Advertisement
Screener

Immunocore Holdings plc (IMCR) Cash and Cash Equivalents

2.8 / 5 stars · 68/120 Roast Me

Immunocore Holdings plc Cash and Cash Equivalents

Immunocore Holdings plc (IMCR) had Cash and Cash Equivalents of $484.92 million as of 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments

us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-06

  • 2026-06-30: Cash and Cash Equivalents, at Carrying Value $484.92M.
  • 2026-03-31: Cash and Cash Equivalents, at Carrying Value $452.68M.
  • 2025-12-31: Cash and Cash Equivalents, at Carrying Value $467.71M.
  • 2025-09-30: Cash and Cash Equivalents, at Carrying Value $498.41M.
Period endCash and Cash Equivalents, at Carrying Value
2026-06-30$484.92M
10-Q · filed 2026-08-06
2026-03-31$452.68M
10-Q · filed 2026-05-06
2025-12-31$467.71M
10-Q · filed 2026-08-06
2025-09-30$498.41M
10-Q · filed 2025-11-06
2025-06-30$487.93M
10-Q · filed 2025-08-07
2025-03-31$476.85M
10-Q · filed 2025-05-07
2024-12-31$455.73M
10-K · filed 2026-02-25
2024-09-30$537.77M
10-Q · filed 2024-11-06
2024-06-30$504.99M
10-Q · filed 2024-08-08
2024-03-31$832.82M
10-Q · filed 2024-05-08
2023-12-31$442.63M
10-K · filed 2025-02-26
2022-12-31$402.47M
10-K · filed 2024-02-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
Taysha Gene Therapies, Inc. (TSHA)United States$1.564B-14.80
Hemab Therapeutics Holdings, Inc. (COAG)United States$1.672B
NOVAVAX INC (NVAX)United States$1.748B-6.26
Inhibrx Biosciences, Inc. (INBX)United States$1.477B-10.08
Maze Therapeutics, Inc. (MAZE)United States$1.457B-12.40
Vir Biotechnology, Inc. (VIR)United States$1.814B-6.85
Vericel Corp (VCEL)United States$2.011B93.97
Replimune Group, Inc. (REPL)United States$1.186B-3.13
RECURSION PHARMACEUTICALS, INC. (RXRX)United States$2.080B-3.78
Kodiak Sciences Inc. (KOD)United States$2.090B-10.12